| 0.459 -0.008 (-1.73%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.6 | 1-year : | 0.72 |
| Resists | First : | 0.51 | Second : | 0.61 |
| Pivot price | 0.45 |
|||
| Supports | First : | 0.34 | Second : | 0.29 |
| MAs | MA(5) : | 0.47 |
MA(20) : | 0.47 |
| MA(100) : | 0.66 |
MA(250) : | 1.1 |
|
| MACD | MACD : | -0.1  |
Signal : | -0.1 |
| %K %D | K(14,3) : | 45.8 |
D(3) : | 46.5 |
| RSI | RSI(14): 47.3 |
|||
| 52-week | High : | 2.21 | Low : | 0.34 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ ME ] has closed below upper band by 47.8%. Bollinger Bands are 22% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.48 - 0.49 | 0.49 - 0.49 |
| Low: | 0.44 - 0.45 | 0.45 - 0.45 |
| Close: | 0.45 - 0.46 | 0.46 - 0.46 |
23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.
Thu, 18 Apr 2024
23andMe CEO Anne Wojcicki Plans to Take Company Private - The Wall Street Journal
Thu, 18 Apr 2024
23andMe Jumps as CEO Floats Taking DNA Tester Private - Bloomberg
Thu, 18 Apr 2024
23andMe stock jumps as CEO plans to take company private - Investing.com
Thu, 18 Apr 2024
23andMe May Disappear as Public Stock - 24/7 Wall St.
Tue, 16 Apr 2024
Here's Why We're A Bit Worried About 23andMe Holding's (NASDAQ:ME) Cash Burn Situation - Simply Wall St
Thu, 08 Feb 2024
23andMe shares slide more than 15% as lower services revenue hits Q3 results - MarketWatch
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Diagnostics & Research
|
|
| Shares Out | 315 (M) |
| Shares Float | 312 (M) |
| Held by Insiders | 3.9 (%) |
| Held by Institutions | 43.1 (%) |
| Shares Short | 32,880 (K) |
| Shares Short P.Month | 32,680 (K) |
| EPS | -1.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.77 |
| Profit Margin | -210.5 % |
| Operating Margin | -180.9 % |
| Return on Assets (ttm) | -26.2 % |
| Return on Equity (ttm) | -92.6 % |
| Qtrly Rev. Growth | -33.3 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.78 |
| EBITDA (p.s.) | -1.01 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -184 (M) |
| Levered Free Cash Flow | -116 (M) |
| PE Ratio | -0.42 |
| PEG Ratio | 0 |
| Price to Book value | 0.58 |
| Price to Sales | 0.58 |
| Price to Cash Flow | -0.79 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|